Inflacam Granules for Horses

País: Australia

Idioma: inglés

Fuente: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Ingredientes activos:

MELOXICAM

Disponible desde:

CHANELLE PHARMACEUTICALS MANUFACTURING LIMITED

formulario farmacéutico:

ORAL GRANULES, PELLETS

Composición:

MELOXICAM UNGROUPED Active 330.0 mg/Sa

Unidades en paquete:

100sachets; 20 sachets

clase:

VM - Veterinary Medicine

Área terapéutica:

MUSCULOSKELETAL SYSTEM

Resumen del producto:

Poison schedule: 4; Withholding period: ; Host/pest details: HORSE: [MUSCULOSKELETAL CONDITIONS]

Estado de Autorización:

Registered

Fecha de autorización:

2023-07-01

Información para el usuario

Product Name:
APVMA Approval No:
Inflacam Granules for Horses
87755/119164
Label Name:
Inflacam Granules for Horses
Signal Headings:
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Constituent
Statements:
Each sachet contains 330 mg MELOXICAM
Claims:
Alleviation of inflammation and pain in both acute and chronic
musculo-skeletal disorders in
horses.
Net Contents:
20 sachets
100 sachets
Directions for Use:
Restraints:
DO NOT USE in horses that may be used for human consumption.
Contraindications:
Contraindicated for use in pregnant or lactating mares as no data has
been established.
Contraindicated for use in horses less than 6 weeks of age.
Contraindicated for use in animals suffering from gastrointestinal
disorders, such as
irritation, haemorrhage and gastric ulceration. Contraindicated for
use in animals suffering
from impaired hepatic, cardiac or renal function and haemorrhagic
disorders or where there
is evidence of individual hypersensitivity to the active substance.
Contraindicated for concurrent administration with glucocorticoids or
other NSAIDs, or with
anti-coagulant agents.
Precautions:
Avoid introduction of contamination during use.
Avoid use in dehydrated, hypovolaemic or hypotensive animals, as there
is a potential risk
of increased renal toxicity.
If adverse reactions occur, treatment should be discontinued and the
advice of a
veterinarian should be sought. RLP APPROVED
Side Effects:
Reversible side effects consistent with the use of non-steroidal
anti-inflammatory drugs
(NSAIDs) may be observed, e.g. slight urticaria and diarrhoea. In very
rare cases loss of
appetite, lethargy, abdominal pain and colitis may occur. In very rare
cases anaphylactoid
reactions which may be serious (including fatal) may occur and should
be treated
symptomatically. If adverse reactions occur, treatment should be
discontinued and the
advice of a veterinarian should be sought.
Overdose:
In the case of overdosing a symptomatic treatment should be initiated.
Dosage and
Administration:
For